Market Cap

PolyPeptide Group AG Market Capitalization:

CHF575.8 Million

CHF as of July 1, 2023

US$643.6 Million

business PolyPeptide Group AG Company Profile

PolyPeptide Group AG Main Stock Listing

show_chart SIX: PPGN

Market Capitalization History of PolyPeptide Group AG

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Drug Manufacturers—Specialty & Generic
Company Market Cap (USD)
Zoetis Inc. $78.54 B
MERCK Kommanditgesellschaft auf Aktien $70.69 B
Takeda Pharmaceutical Company Limited $46.59 B
Haleon plc $37.99 B
Eisai Co. Ltd $17.26 B
Sector: Healthcare
Company Market Cap (USD)
UnitedHealth Group $428.70 B
Lilly $417.05 B
Johnson & Johnson $412.24 B
Novo Nordisk $329.83 B
Merck $275.82 B

Yearly evolution of PolyPeptide Group AG market cap

Date Market Cap YoY Change
Jan. 1, 2023 CHF909.0 M -70.24%
Jan. 1, 2022 CHF3.05 B

Market capitalization is calculated from the opening stock price at the beginning of each year.

PolyPeptide Group AG Categories

Switzerland languages Healthcare languages Drug Manufacturers—Specialty & Generic
Switzerland Healthcare Switzerland Drug Manufacturers—Specialty & Generic

Stocks & Indices

PolyPeptide Group AG has the following listings and related stock indices.


Stock: SIX: PPGN

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.